Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
OwnerKevin Challon Glenn, Chris P. Carron +3inventors
InventorsKEVIN CHALLON GLENN, CHRIS P. CARRON, LARRY P. FEIGEN, JIMMY D. PAGE, JODI A. PEGG
Life of this patent
Estimating the term…
Abstract
The invention provides a process to restore platelet aggregation by the administration of antibody combining site-containing molecules that specifically bind to a specific class of reversibly-bound GPIIb/IIIa fibrinogen receptor antagonist compounds.
Claims22
A process for restoring platelet aggregation in the blood of a mammalian host treated with a reversibly-bound GPIIb/IIIa receptor antagonist compound that exhibits a plasma half-life of about two hours to about thirty-six hours, and a GPIIb/IIIa receptor off-rate of about 0.7/seconds (t1/2˜1 second) to 0.012/seconds (t1/2˜60 seconds), or a pharmaceutically acceptable salt of said compound, that comprises the steps of:
- (a) contacting the blood of said host with a therapeutically effective amount of antibody combining site-containing molecules that specifically bind to said GPIIb/IIIa receptor antagonist compound to form antibody-treated blood;
- and
- (b) maintaining said antibody-treated blood for a period of time sufficient to restore platelet aggregation.
A process for restoring platelet aggregation in the blood of a mammalian host treated with a reversibly-bound GPIIb/IIIa receptor antagonist compound that exhibits a plasma half-life of about two hours to about thirty-six hours, and a GPIIb/IIIa receptor off-rate of about 0.7/seconds (t1/2˜1 second) to 0.012/seconds (t1/2˜60 seconds), or a pharmaceutically acceptable salt of said compound, that comprises the steps of:
- (a) contacting the blood of said host in vivo with a therapeutically effective amount of antibody combining site-containing molecules that specifically bind to said GPIIb/IIIa receptor antagonist compound to form antibody-treated blood;
- and
- (b) maintaining said antibody-treated blood for a period of time sufficient to restore platelet aggregation.
Dependencies are inferred from the claim text.